Search Results - hyunjin+kang

4 Results Sort By:
Cancer treatment through hTERT inhibition
Title: Cancer Treatment Through hTERT Inhibition Invention: The invention is a small molecule that reduces human telomerase reverse transcriptase (hTERT), which is highly activated in cancer cells. Background: In 2010, approximately 73,599 U.S. patients were diagnosed with melanoma with 8,700 of those incidences resulting in death. A hallmark of cancer,...
Published: 1/7/2025   |   Inventor(s): Laurence Hurley, Vijay Gokhale, HyunJin Kang, Kui Wu
Keywords(s):  
Category(s): Technology Classifications > Healthcare Portfolios > Oncology
Inhibition of T Cell Differentiation and Senescence by Overexpression of Transcription Factor c-Myb
Abstract: Adoptive Cell Therapy (ACT) is a promising technique that uses a patient's own T cells to treat cancer. The process requires removing and engineering a patient's T cells to express a chimeric antigen receptor (CAR) or T cell receptor (TCR) that targets a specific cancer antigen. When the modified T cells are reintroduced into the patient,...
Published: 4/8/2024   |   Inventor(s): Sanjivan Gautam, Yun Ji, Luca Gattinoni
Keywords(s): act, Adoptive Cell Transfer, CANCER, CAR, chimeric antigen receptor, Gattinoni, Immunotherapy, Infectious Disease, Stem Cell, T cell, T Cell Receptor, TCR
Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing
Overexpression of Phf19 on T Cells Enhances Therapeutic Effects of T Cell-Based Therapies (such as Chimeric Antigen Receptor [CAR] Therapies)
Abstract: T cell-based immunotherapy (such as CAR therapies) is a promising approach for the treatment of several cancers. However, T cells currently employed for various T cell-based immunotherapies are usually senescent and terminally differentiated leading to poor proliferative and survival capacity, limiting their therapeutic effectiveness once...
Published: 4/8/2024   |   Inventor(s): Yun Ji, Luca Gattinoni
Keywords(s): CAR-T Therapy, CD8, chimeric antigen receptor, Gattinoni, Phf19, T cell
Category(s): TherapeuticArea > Oncology, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics
Chance-Constrained Optimization for Treatment of Prostate and Other Cancers in Intensity-Modulated Proton Therapy
The quality of IMPT treatment plans may be drastically diminished by uncertainties such as proton range and patient setup errors. If these uncertainties are not figured into treatment planning, the dose distribution that the patient receives may not be the same as the planned dose distribution. New treatment plans, which include optimized software/programming,...
Published: 12/18/2024   |   Inventor(s): Jianming Liang, Yu An, Wei Liu
Keywords(s):  
Category(s): Computing & Information Technology, Life Science (All LS Techs), Medical Imaging